| | CHEST: Esmolol in the treatment of multifocal atrial tachycardia (Site not responding. Last check: 2007-10-12) |
 | | Esmolol, an ultra-short-acting intravenous [beta]-blocker, has cardioselectivity similar to metoprolol, and has been reported to be safe and effective in the treatment of supraventricular tachycardias.[9-13] Its characteristics include a distribution half-life of 2 min, elimination half-life of 9 mins, and a duration of action of 5 to 10 min. |
 | | Although a number of reports have noted the usefulness of esmolol in the treatment of supraventricular tachycardias, information specifically addressing its dose and therapeutic responses in the treatment of MAT are lacking. |
 | | Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachycardias: a multicenter double-blind clinical trial. |
| www.findarticles.com /p/articles/mi_m0984/is_n6_v101/ai_12407550 (1123 words) |